Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 13 de 13
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Front Immunol ; 10: 1757, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31396241

RESUMEN

Alessandro Moretta was Professor of Histology at University of Brescia from 1994 to 1997. It was in that period that we met and started a collaboration that continued in the years to follow. He immediately involved us in the production of monoclonal antibodies (mAbs) that allowed the identification and fine characterization of novel receptor molecules that were able to activate or inhibit human Natural Killer cell function, including several antibodies specific for Natural Cytotoxicity Receptor (NCR) and Killer-cell Immunoglobulin-like Receptor (KIR) molecules. These reagents, generated in our laboratory in Brescia, contributed to complete the studies aimed to characterize innate lymphoid NK cells, that had been initiated by Alessandro and his brother Lorenzo in Genoa. Soon, we identified an anti-KIR3DL2 that was subsequently shown to be helpful for the diagnosis and treatment of various forms of cutaneous T cell lymphoma. While in Brescia, Alessandro established a partnership with those of us who were working in the Department of Pediatrics; together, in short time we tackled the goal of studying the role of NK cells in patients with primary immunodeficiencies. This collaboration led to novel discoveries that shed light on the critical role played by NK cells in the immune response against virus and tumors in humans, as best exemplified by our characterization of the molecular mechanisms of impaired control of Epstein-Barr Virus (EBV) infection in patients with X-linked lymphoproliferative (XLP) disease. After Alessandro left Brescia to return to Genoa, our collaboration continued with the same enthusiasm, and even from a distance he remained an extraordinary example of an inspirational and generous mentor. This review is a sign of our gratitude to a mentor and a friend whom we deeply miss.


Asunto(s)
Infecciones por Virus de Epstein-Barr , Herpesvirus Humano 4 , Células Asesinas Naturales/inmunología , Trastornos Linfoproliferativos , Enfermedades de Inmunodeficiencia Primaria , Receptores KIR , Infecciones por Virus de Epstein-Barr/genética , Infecciones por Virus de Epstein-Barr/historia , Infecciones por Virus de Epstein-Barr/inmunología , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/inmunología , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Trastornos Linfoproliferativos/genética , Trastornos Linfoproliferativos/historia , Trastornos Linfoproliferativos/inmunología , Enfermedades de Inmunodeficiencia Primaria/genética , Enfermedades de Inmunodeficiencia Primaria/historia , Enfermedades de Inmunodeficiencia Primaria/inmunología , Receptores KIR/genética , Receptores KIR/historia , Receptores KIR/inmunología
4.
Curr Top Microbiol Immunol ; 390(Pt 1): 3-15, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26424640

RESUMEN

An account is given of the experiences and events which led to a search being undertaken for a causative virus in the recently described Burkitt's lymphoma and of the steps which ultimately culminated in the discovery of the new human herpesvirus which came to be known as Epstein-Barr virus (EBV).


Asunto(s)
Infecciones por Virus de Epstein-Barr/virología , Herpesvirus Humano 4/aislamiento & purificación , Virología/historia , Animales , Infecciones por Virus de Epstein-Barr/historia , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/fisiología , Herpesvirus Humano 4/ultraestructura , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Recursos Humanos
5.
Curr Top Microbiol Immunol ; 390(Pt 1): 17-22, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26424641

RESUMEN

This is a brief history of our collaborative work with Werner and Gertrude Henle, Francis Wiener, George and Yanke Manolov, and others on the association of Epstein-Barr virus (EBV) with Burkitt lymphoma and other human tumors. Special emphasis is put on the question where EBV is a true cancer virus.


Asunto(s)
Infecciones por Virus de Epstein-Barr/virología , Herpesvirus Humano 4/fisiología , Neoplasias/virología , Animales , Infecciones por Virus de Epstein-Barr/historia , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/aislamiento & purificación , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Neoplasias/historia
6.
Curr Top Microbiol Immunol ; 390(Pt 1): 23-42, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26424642

RESUMEN

Early research on Epstein-Barr virus (EBV) developed from serological observations that were made soon after the discovery of the virus. Indeed, the definition of the humoral response to a variety of EBV proteins dominated the early literature and was instrumental in providing the key evidence for the association of the virus with infectious mononucleosis (IM), Burkitt's lymphoma (BL), and nasopharyngeal carcinoma (NPC). Each of these disease associations involved a distinct pattern of serological reactivity to the EBV membrane antigens (MA), early antigens (EA), and the EBV nuclear antigen (EBNA). When it became generally accepted that the marked lymphocytosis , which is a hallmark of acute IM, was dominated by T cells, considerable effort was directed toward untangling the specificities that might be associated with restricting the proliferation of newly infected B cells. Early evidence was divided between support for both EBV non-specific and/or HLA non-restricted components. However, all results needed to be reassessed in light of the observation that T cells died by apoptosis within hours of separation from fresh blood from acute IM patients. The observation that EBV-infected cultures from immune (but not non-immune) individuals began to die (termed regression) about 10 days post-seeding, provided the first evidence of a specific memory response which was apparently capable of controlling the small pool of latently infected B cells which all immune individuals possess. In this early era, CD8(+) T cells were thought to be the effector population responsible for this phenomenon, but later studies suggested a role for CD4(+) cells. This historical review includes reference to key early observations in regard to both the specific humoral and cellular responses to EBV infection from the time of the discovery of the virus until 1990. As well, we have included personal recollections in regard to the events surrounding the discovery of the memory T cell response since we believe they add a human dimension to a chapter focussed on early history.


Asunto(s)
Infecciones por Virus de Epstein-Barr/inmunología , Herpesvirus Humano 4/inmunología , Inmunidad Celular , Inmunidad Humoral , Animales , Linfocitos T CD8-positivos/inmunología , Linfocitos T CD8-positivos/virología , Infecciones por Virus de Epstein-Barr/historia , Infecciones por Virus de Epstein-Barr/virología , Antígenos Nucleares del Virus de Epstein-Barr/genética , Antígenos Nucleares del Virus de Epstein-Barr/metabolismo , Herpesvirus Humano 4/genética , Herpesvirus Humano 4/fisiología , Historia del Siglo XX , Humanos , Proteínas de la Matriz Viral/genética , Proteínas de la Matriz Viral/metabolismo , Virología/historia , Recursos Humanos
7.
Curr Top Microbiol Immunol ; 390(Pt 1): 267-85, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26424650

RESUMEN

Endemic Burkitt's lymphoma (BL) remains the most prevalent pediatric cancer in sub-Saharan Africa even though it was the first human cancer with a viral etiology described over 50 years ago. Epstein-Barr virus (EBV) was discovered in a BL tumor in 1964 and has since been implicated in other malignancies. The etiology of endemic BL has been linked to EBV and Plasmodium falciparum malaria co-infection. While epidemiologic studies have yielded insight into EBV infection and the etiology of endemic BL, the modulation of viral persistence in children by malaria and deficits in EBV immunosurveillance has more recently been reified. Renewed efforts to design prophylactic and therapeutic EBV vaccines provide hope of preventing EBV-associated BL as well as increasing the ability to cure this cancer.


Asunto(s)
Linfoma de Burkitt/virología , Infecciones por Virus de Epstein-Barr/virología , Herpesvirus Humano 4/fisiología , Animales , Linfoma de Burkitt/historia , Linfoma de Burkitt/inmunología , Infecciones por Virus de Epstein-Barr/historia , Infecciones por Virus de Epstein-Barr/inmunología , Herpesvirus Humano 4/genética , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Monitorización Inmunológica
8.
Pathologe ; 35(2): 143-51, 2014 Mar.
Artículo en Alemán | MEDLINE | ID: mdl-24619524

RESUMEN

In 1921 Alexander Schmincke established the visionary concept of a clinically and histomorphologically defined carcinoma entity of different lymphoepithelial organs that he named "lymphoepithelioma". This nowadays mainly comprises non-keratinizing oropharyngeal carcinomas frequently associated with human papillomavirus (HPV) and non-keratinizing nasopharyngeal carcinomas mostly associated with Epstein-Barr virus (EBV). The term lymphoepithelioma was originally defined by A. Schmincke and J. Ewing as a combined clinical and histological tumor entity of lymphoepithelial organs. The main reason for the longstanding terminological confusion regarding the term lymphoepithelioma is based on the fact that lateron a pure histological interpretation (lymphoepithelial differentiation) caused an artificial and nonreproducible exclusion of tumors with transitional and basaloid differentiation. For the forthcoming new WHO classification it has been suggested that squamous cell carcinoma of the head and neck should no longer be classified according to the heterogeneous histological differentiation but according to etiopathogenetic criteria (e.g. HPV-related, EBV-related, nicotine and alcohol-related). This proposed classification corresponds much better to the prognosis and therapy and would represent a late acknowledgement of Schmincke's visionary concept of a clinically and histomorphologically defined tumor entity. In addition, the ongoing terminological confusion over the heterogeneous and prognostically weak spectrum of histological differentiation would subside.


Asunto(s)
Carcinoma de Células Escamosas/historia , Infecciones por Virus de Epstein-Barr/historia , Neoplasias Nasofaríngeas/historia , Neoplasias Orofaríngeas/historia , Infecciones por Papillomavirus/historia , Terminología como Asunto , Carcinoma de Células Escamosas/patología , Infecciones por Virus de Epstein-Barr/patología , Alemania , Historia del Siglo XX , Humanos , Neoplasias Nasofaríngeas/patología , Neoplasias Orofaríngeas/patología , Orofaringe/patología , Infecciones por Papillomavirus/patología , Pronóstico
9.
Histopathology ; 59(4): 679-91, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-22014049

RESUMEN

AIMS: To revise 25 cases selected from Karl Lennert's personal archive (21) and Bologna and Frankfurt Registries (four) because of cytological similarities. METHODS AND RESULTS: All cases were provided with paraffin blocks and studied by immunohistochemistry and molecular techniques. While phenotyping was very informative, among molecular studies only EBER in situ-hybridization (ISH) was successful. Twenty-two cases were concluded as peripheral T cell lymphomas (PTCL). Of these, six were reclassified as angioimmunoblastic T cell lymphoma (AITL), 13 as PTCL, not otherwise specified (NOS), including four follicular variants and one tumour with T-zone pattern, and three as borderline tumours between AITL and PTCL/NOS. All these cases consisted homogeneously of small/medium-sized elements with mild nuclear atypia and an evident rim of clear/pale cytoplasm. On immunohistochemistry, they regularly expressed three to six follicular helper T cell (FTH)-associated markers. EBER-ISH revealed scattered EBV-infected B cells in all tumours except those with 'follicular' growth pattern. The content of follicular dendritic cells and high-endothelial venules varied significantly depending on the histotype. CONCLUSIONS: This study shows that: (i) historical material can be still employed usefully, and (ii) the FTH-phenotype corresponds to a broad spectrum of PTCLs that might form a new category to be validated in future molecular and clinicopathological analyses.


Asunto(s)
Linfoma Folicular/patología , Linfoma de Células T Periférico/patología , Linfocitos T Colaboradores-Inductores/patología , Bancos de Tejidos , Linfocitos B/patología , Linfocitos B/virología , Infecciones por Virus de Epstein-Barr/complicaciones , Infecciones por Virus de Epstein-Barr/historia , Infecciones por Virus de Epstein-Barr/patología , Historia del Siglo XX , Humanos , Inmunohistoquímica , Hibridación in Situ , Linfoma Folicular/historia , Linfoma Folicular/virología , Linfoma de Células T Periférico/historia , Linfoma de Células T Periférico/virología , Fenotipo , ARN Viral/análisis , Sistema de Registros , Bancos de Tejidos/historia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA